France’s PEP-Therapy Cell-Penetrating Peptides To Teach Cancer Cells How ‘To Die Again’
Novel Product First In A New Drug Class
Emerging Company Profile: Armed with fresh funds, French spin-out PEP-Therapy will begin a clinical proof of concept study assessing its lead therapeutic peptide as a potential treatment for metastatic triple-negative breast cancer and platinum-resistant ovarian cancer.
